(ENTA) Enanta Pharmaceuticals - Ratings and Ratios
Hepatitis Treatment, Antiviral Drugs, Small Molecule Medications
ENTA EPS (Earnings per Share)
ENTA Revenue
Description: ENTA Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for treating viral infections and liver diseases. Their product pipeline includes several promising candidates, such as EDP-514 for hepatitis B virus (HBV), EDP-938 and EDP-323 for respiratory syncytial virus (RSV), and EDP-235 for human coronaviruses. The company has a successful commercialized product, Glecaprevir, for treating hepatitis C virus (HCV).
From a strategic perspective, Enantas collaboration with Abbott Laboratories to develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir, is a significant strength. This partnership has likely contributed to the companys revenue and validates their research and development capabilities. Key performance indicators (KPIs) to monitor Enantas progress include the advancement of their pipeline candidates through clinical trials, particularly the Phase II trials for EDP-235 and EDP-323.
To further evaluate Enantas potential, we can examine additional KPIs such as their cash runway, research and development (R&D) expenses as a percentage of revenue, and the revenue growth from their commercialized products. Given the companys negative return on equity (RoE) of -79.83, it is essential to assess their burn rate and ensure they have sufficient funds to continue developing their pipeline without significant financial strain. A market capitalization of $164.60M and a current stock price of $6.96 indicate a relatively small-cap stock with potential for volatility.
From a trading perspective, monitoring Enantas stock price movement relative to its short-term and long-term moving averages (SMA20, SMA50, and SMA200) can provide insights into market sentiment and potential trends. The stocks average true range (ATR) of 0.40, representing a 5.75% daily price movement, suggests moderate volatility. As a Trading Analyst, it is crucial to weigh these factors and KPIs when evaluating Enanta Pharmaceuticals as a potential investment opportunity.
ENTA Stock Overview
| Market Cap in USD | 189m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-03-21 |
ENTA Stock Ratings
| Growth Rating | -69.3% |
| Fundamental | 21.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -46.9% |
| Analyst Rating | 3.67 of 5 |
ENTA Dividends
Currently no dividends paidENTA Growth Ratios
| Growth Correlation 3m | 61.8% |
| Growth Correlation 12m | -29.8% |
| Growth Correlation 5y | -82.8% |
| CAGR 5y | -48.13% |
| CAGR/Max DD 3y | -0.52 |
| CAGR/Mean DD 3y | -0.62 |
| Sharpe Ratio 12m | -1.38 |
| Alpha | -53.29 |
| Beta | 0.670 |
| Volatility | 63.06% |
| Current Volume | 400.9k |
| Average Volume 20d | 128.8k |
| Stop Loss | 6.9 (-7.5%) |
| Signal | -2.33 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-92.0m TTM) > 0 and > 6% of Revenue (6% = 3.89m TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA -3.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 274.9% (prev 317.3%; Δ -42.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -23.2m > Net Income -92.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (21.3m) change vs 12m ago 0.67% (target <= -2.0% for YES) |
| Gross Margin 96.03% (prev 96.49%; Δ -0.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 18.52% (prev 18.04%; Δ 0.48pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.68 (EBITDA TTM -83.6m / Interest Expense TTM 7.88m) >= 6 (WARN >= 3) |
Altman Z'' -3.74
| (A) 0.59 = (Total Current Assets 222.7m - Total Current Liabilities 44.5m) / Total Assets 301.0m |
| (B) -1.28 = Retained Earnings (Balance) -386.2m / Total Assets 301.0m |
| warn (B) unusual magnitude: -1.28 — check mapping/units |
| (C) -0.24 = EBIT TTM -84.1m / Avg Total Assets 349.9m |
| (D) -1.74 = Book Value of Equity -386.2m / Total Liabilities 221.8m |
| Total Rating: -3.74 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 20.98
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -50.26% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 2.62 = -0.18 |
| 5. Debt/Ebitda -2.48 = -2.50 |
| 6. ROIC - WACC -85.73% = -12.50 |
| 7. RoE -89.02% = -2.50 |
| 8. Rev. Trend -70.26% = -5.27 |
| 9. EPS Trend 68.62% = 3.43 |
What is the price of ENTA shares?
Over the past week, the price has changed by -16.27%, over one month by -6.75%, over three months by +2.47% and over the past year by -36.83%.
Is Enanta Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ENTA is around 4.77 USD . This means that ENTA is currently overvalued and has a potential downside of -36.06%.
Is ENTA a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ENTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.6 | 148.9% |
| Analysts Target Price | 18.6 | 148.9% |
| ValueRay Target Price | 5.1 | -31.4% |
Last update: 2025-09-08 04:37
ENTA Fundamental Data Overview
CCE Cash And Equivalents = 204.1m USD (Cash And Short Term Investments, last quarter)
P/S = 2.9194
P/B = 2.3864
Beta = 0.845
Revenue TTM = 64.8m USD
EBIT TTM = -84.1m USD
EBITDA TTM = -83.6m USD
Long Term Debt = 177.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 30.1m USD (from shortTermDebt, last quarter)
Debt = 207.3m USD (Calculated: Short Term 30.1m + Long Term 177.2m)
Net Debt = 162.3m USD (from netDebt column, last quarter)
Enterprise Value = 192.4m USD (189.2m + Debt 207.3m - CCE 204.1m)
Interest Coverage Ratio = -10.68 (Ebit TTM -84.1m / Interest Expense TTM 7.88m)
FCF Yield = -50.26% (FCF TTM -96.7m / Enterprise Value 192.4m)
FCF Margin = -149.2% (FCF TTM -96.7m / Revenue TTM 64.8m)
Net Margin = -142.0% (Net Income TTM -92.0m / Revenue TTM 64.8m)
Gross Margin = 96.03% ((Revenue TTM 64.8m - Cost of Revenue TTM 2.57m) / Revenue TTM)
Tobins Q-Ratio = -0.50 (set to none) (Enterprise Value 192.4m / Book Value Of Equity -386.2m)
Interest Expense / Debt = 0.78% (Interest Expense 1.62m / Debt 207.3m)
Taxrate = 21.0% (US default)
NOPAT = -84.1m (EBIT -84.1m, no tax applied on loss)
Current Ratio = 5.00 (Total Current Assets 222.7m / Total Current Liabilities 44.5m)
Debt / Equity = 2.62 (Debt 207.3m / last Quarter total Stockholder Equity 79.3m)
Debt / EBITDA = -2.48 (Net Debt 162.3m / EBITDA -83.6m)
Debt / FCF = -2.14 (Debt 207.3m / FCF TTM -96.7m)
Total Stockholder Equity = 103.4m (last 4 quarters mean)
RoA = -30.57% (Net Income -92.0m, Total Assets 301.0m )
RoE = -89.02% (Net Income TTM -92.0m / Total Stockholder Equity 103.4m)
RoCE = -29.98% (Ebit -84.1m / (Equity 103.4m + L.T.Debt 177.2m))
RoIC = -81.36% (NOPAT -84.1m / Invested Capital 103.4m)
WACC = 4.37% (E(189.2m)/V(396.5m) * Re(8.48%)) + (D(207.3m)/V(396.5m) * Rd(0.78%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.31%
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -96.7m)
EPS Correlation: 68.62 | EPS CAGR: 21.59% | SUE: 0.07 | # QB: False
Revenue Correlation: -70.26 | Revenue CAGR: -3.70%
Additional Sources for ENTA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle